Scancell Holdings plc (LON:SCLP – Get Free Report) shares passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of GBX 14.01 and traded as low as GBX 9.36. Scancell shares last traded at GBX 9.45, with a volume of 3,120,094 shares changing hands.
Scancell Stock Performance
The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The firm has a market capitalization of £126.17 million, a P/E ratio of -16.91 and a beta of 0.69. The stock has a fifty day moving average of GBX 9.69 and a 200-day moving average of GBX 13.99.
Scancell Company Profile
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
